These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 28099318

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC, Yu Y, VanderBeek BL.
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y, Matsushima H, Kinoshita S, Senoo T, Tochikubo T, Kadonosono K.
    Ophthalmologica; 2011 Oct; 226(3):145-50. PubMed ID: 21811052
    [Abstract] [Full Text] [Related]

  • 7. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y, Tan CS.
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [Abstract] [Full Text] [Related]

  • 8. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, DeCroos FC, Garg SJ, Hsu J.
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [Abstract] [Full Text] [Related]

  • 9. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
    Haddock LJ, Ramsey DJ, Young LH.
    Semin Ophthalmol; 2014 May; 29(5-6):257-62. PubMed ID: 25325851
    [Abstract] [Full Text] [Related]

  • 10. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S, Alsulaiman SM, Alrushood AA, Almasaud J, Arevalo JF.
    Middle East Afr J Ophthalmol; 2016 May; 23(1):60-3. PubMed ID: 26957840
    [Abstract] [Full Text] [Related]

  • 11. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, Martin DF, Prenner JL, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
    [Abstract] [Full Text] [Related]

  • 12. Bilateral endophthalmitis following bilateral same-day anti-VEGF injections.
    Sepetis AE, Clarke B, Gupta B.
    Acta Ophthalmol; 2021 Feb; 99(1):e131-e133. PubMed ID: 32533656
    [No Abstract] [Full Text] [Related]

  • 13. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital.
    Zafar S, Hamid A, Bin Mahmood SU, Burq MA, Maqsood N.
    Can J Ophthalmol; 2018 Apr; 53(2):94-97. PubMed ID: 29631833
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M, Storey PP, Levin HJ, Obeid A, Patel SN, Kuley B, Hsu J, Spirn MJ, Fineman M, Klufas MA, Gupta O, Ho AC, Garg SJ.
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Inman ZD, Anderson NG.
    Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
    [Abstract] [Full Text] [Related]

  • 19. Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections.
    Israilevich RN, Mansour H, Patel SN, Garg SJ, Klufas MA, Yonekawa Y, Regillo CD, Hsu J.
    Ophthalmology; 2024 Jun; 131(6):667-673. PubMed ID: 38182029
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.